Statements in which the resource exists.
SubjectPredicateObjectContext
pubmed-article:19914397rdf:typepubmed:Citationlld:pubmed
pubmed-article:19914397lifeskim:mentionsumls-concept:C1280477lld:lifeskim
pubmed-article:19914397lifeskim:mentionsumls-concept:C2718059lld:lifeskim
pubmed-article:19914397pubmed:issue3-4lld:pubmed
pubmed-article:19914397pubmed:dateCreated2010-2-9lld:pubmed
pubmed-article:19914397pubmed:abstractTextPersonalized medicine is the tailoring of therapies to defined subsets of patients based on their likelihood to respond to therapy or their risk of adverse events. The advent of improved genomic tools has greatly hastened our understanding of the molecular pathology of diseases, enabling us to redefine disease at the molecular level. The development of molecularly targeted therapies, coupled with improved diagnostic criteria, holds the promise of delivering a new paradigm in drug development. But how far have we come, and how close is personalized medicine to delivering on its promise?lld:pubmed
pubmed-article:19914397pubmed:languageenglld:pubmed
pubmed-article:19914397pubmed:journalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:19914397pubmed:citationSubsetIMlld:pubmed
pubmed-article:19914397pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:19914397pubmed:statusMEDLINElld:pubmed
pubmed-article:19914397pubmed:monthFeblld:pubmed
pubmed-article:19914397pubmed:issn1878-5832lld:pubmed
pubmed-article:19914397pubmed:authorpubmed-author:BatesStewartSlld:pubmed
pubmed-article:19914397pubmed:copyrightInfoCopyright (c) 2009 Elsevier Ltd. All rights reserved.lld:pubmed
pubmed-article:19914397pubmed:issnTypeElectroniclld:pubmed
pubmed-article:19914397pubmed:volume15lld:pubmed
pubmed-article:19914397pubmed:ownerNLMlld:pubmed
pubmed-article:19914397pubmed:authorsCompleteYlld:pubmed
pubmed-article:19914397pubmed:pagination115-20lld:pubmed
pubmed-article:19914397pubmed:meshHeadingpubmed-meshheading:19914397...lld:pubmed
pubmed-article:19914397pubmed:meshHeadingpubmed-meshheading:19914397...lld:pubmed
pubmed-article:19914397pubmed:meshHeadingpubmed-meshheading:19914397...lld:pubmed
pubmed-article:19914397pubmed:meshHeadingpubmed-meshheading:19914397...lld:pubmed
pubmed-article:19914397pubmed:meshHeadingpubmed-meshheading:19914397...lld:pubmed
pubmed-article:19914397pubmed:meshHeadingpubmed-meshheading:19914397...lld:pubmed
pubmed-article:19914397pubmed:meshHeadingpubmed-meshheading:19914397...lld:pubmed
pubmed-article:19914397pubmed:meshHeadingpubmed-meshheading:19914397...lld:pubmed
pubmed-article:19914397pubmed:year2010lld:pubmed
pubmed-article:19914397pubmed:articleTitleProgress towards personalized medicine.lld:pubmed
pubmed-article:19914397pubmed:affiliationDirector Biomarker Discovery, Biopharm R&D, GSK Medicines Research Centre, Gunnels Wood Road, Stevenage, Hertfordshire SG1 2NY, UK. stewart.a.bates@gsk.comlld:pubmed
pubmed-article:19914397pubmed:publicationTypeJournal Articlelld:pubmed
pubmed-article:19914397pubmed:publicationTypeReviewlld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:19914397lld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:19914397lld:pubmed